Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Novel BTK inhibitor acalabrutinib shows promise in CLL

A novel BTK inhibitor, acalabrutinib, is showing promise in the early clinical trial stages for chronic lymphocytic leukemia (CLL). Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Susan O’Brien, MD, of the University of California, Irvine, CA, discusses the benefits of acalabrutinib over ibrutinib and why this may be. Prof. O’Brien highlights the main studies of this agent for CLL, including as a monotherapy (ACE-CL-001; NCT02029443) and in combination with ACP-319 (ACE-CL-002; NCT02157324) in the relapsed/refractory setting, and in the frontline setting in combination with obinutuzumab (ACE-CL-003; NCT02296918).